Day 1

Gain insight into today’s sessions so you can get the most out of your conference experience.

Understand the priorities of the CDA-AMC’s expanded role in 2025 and its direction into 2026. Assess the impact of this development on your organization by learning about the existing and emerging core functions of Canada’s Drug Agency. Walk away with an action plan on:

• Leading national efforts on a pan-Canadian appropriate use and prescribing program.
• Enhancing patient experience through data and analytics.
• Improving system coordination across Canada.

Advance your market access strategy with direct guidance from the CDA-AMC to align with national priorities and support equitable access for patients across Canada.

Bringing new drugs and treatments to market is often a slow and complex process with multiple layers of regulatory, pricing, and reimbursement evaluations. Source practical tips to:

• Identify procedural and technological inefficiencies and determine how to reduce them where possible.
• Pinpoint common sticking points and roadblocks in market access and discover strategies to navigate them.
• Leverage early engagement with regulatory and reimbursement bodies to accelerate approval timelines.

Improve your approach to market access by addressing inefficiencies at every stage of the approval process.

The landscape of market access for pharmaceutical and healthcare is rapidly changing, presenting both pitfalls and opportunities for the industry to meet patient needs. Understanding key risks and proactively identifying growth opportunities is essential for long-term success. Develop a blueprint to:

• Assess the impact of regulatory changes and explore how the industry can engage effectively with regulators.
• Identify emerging opportunities for growth and innovation and examine how they can enhance patient access.
• Develop strategies to mitigate risks and capitalize on key trends by leveraging data-driven insights, stakeholder collaboration, and adaptive business models.

Bolster your ability to navigate a dynamic pharmaceutical environment to identify emerging opportunities, mitigate evolving risks, and strengthen patient access across Canada.

The definition of ‘value’ as it pertains to market access in Canada can differ depending on the stakeholder perspective. Gain clarity on defining your value. Adopt best practices to:

• Understand how Health Canada approvals and CADTH/INESSS assessments shape value perceptions.
• Align value propositions with public and private insurers, patient advocacy groups, and healthcare providers, ensuring alignment with national and provincial reimbursement frameworks.
• Leverage health economic models, patient outcomes data, and comparator analyses to demonstrate value beyond pricing.

Reduce misalignment among stakeholders by clarifying value in pricing and reimbursement discussions.

Private payers play a crucial role in ensuring Canadians have access to innovative treatments. By bridging the gap between public coverage and out-of-pocket expenses, private insurers help patients receive timely and comprehensive healthcare solutions. Master the success factors to:

• Understand how private payers enhance access to treatment for patients.
• Explore how private payers can collaborate with pharmaceutical companies, healthcare providers, and employers to develop sustainable reimbursement models.
• Examine the role of innovative drug coverage programs, value-based agreements, and digital health solutions in improving patient outcomes.

Heighten collaboration between private payers and healthcare stakeholders to optimize patient access and treatment outcomes.

Real-world evidence (RWE) plays a pivotal role in ensuring that drug prices align with their actual performance in patient populations. Strengthen the case for value-based pricing. Achieve a step-by-step action plan to:

• Provide a broader view of a drug’s actual impact, with scope for dynamic pricing adjustments when drug effectiveness varies across diverse groups.
• Enable performance-based agreements to ensure that patients receive therapies that deliver real benefits without straining healthcare budgets.
• Use measurable outcomes (e.g., reduced hospitalizations, improved disease management) to negotiate reimbursement plans.

Advance the use of RWE to optimize treatment efficacy and align drug costs with measurable outcomes

• Browse through different sponsor booths and source innovative market access expertise.
• Enter your name for a chance to win exciting prizes.
• Take advantage of event-specific offers and special content.

With individual provinces employing various strategies to manage drug costs effectively, develop your best practice in negotiating sustainable pricing whilst ensuring patients have the access they need. Take back to your office strategies to:

• Understand Tiered Pricing Frameworks (TPFs) and how the pCPA evaluates and establishes prices for innovative and generic products entering or exiting the Canadian market.
• Identify when generic substitution of brand-name drugs and other methods to reduce expenditure is appropriate.
• Examine differences across the provinces, where they align, and how they incorporate this when building their pricing models for different drugs.

Optimize collaborative and province-specific tactics to balance cost containment with equitable access to essential medications.

Ensuring timely access to innovative therapies requires strong collaboration between pharmaceutical companies and payers. With rapid advancements in digital health, technology is reshaping how market access strategies are designed and executed. Create a roadmap to:

• Utilize data-driven decision-making through advanced analytics and AI-driven insights to help payers assess drug value based on real-world evidence (RWE).
• Streamline negotiations through digital platforms, cloud-based collaboration, and automated processes.
• Enhance transparency in pricing decisions through blockchain technologies.

Increase effective collaboration across the pharma-payer relationship with the latest technologies to optimize decision-making, streamline processes, and improve access to innovative treatments.

• Visit sponsor booths and experience the next level of market access innovation
• Meet one-on-one with leading solution providers to discuss organizational hurdles.
• Brainstorm solutions and gain new perspectives and ideas.

Hear the latest update on draft guidelines detailing the administrative process for recommending hearings on excessive drug pricing, to enhance transparency and procedural fairness in assessing whether a patented medicine’s price is excessive. Adopt best practices to:

• Learn directly from the PMPRB on how the draft guidelines and recommendations have been asserted.
• Gain clarity on the PMPRB’s interim guidance aimed at expediting price reviews and its impact on market entry timelines.

Master the roadmap for 2026 and beyond in PMPRB strategy to improve pricing processes and ensure timely market access for innovative medicines.

Dive into the evolving landscape of National Pharmacare and its implications for nationwide efforts towards achieving affordable, equitable access to medications across Canada. Source your plan of action with insights on:

• National Pharmacare aiming to unify drug coverage, reduce disparities, and improve affordability for all Canadians.
• Key challenges involving balancing cost-containment with innovation and aligning federal-provincial priorities.
• Stakeholder collaboration from payers to patients being essential for sustainable and equitable access models.

Achieve a comprehensive understanding of the national pharmacare debate and how to prepare for future policy to navigate evolving healthcare landscapes and drive equitable access to medications across Canada.

Step into a dynamic conversation where diverse voices from across the market access landscape share their top three “I wish…” statements — honest, bold, and sometimes surprising. Discover where visions align and where tensions spark in the collective pursuit of better market access. Deepen your knowledge on the future of market access by:

• Hearing candid reflections from key stakeholders, including patient groups, payers, HTA agencies, clinicians, and industry leaders.
• Exploring areas of common ground and identifying key divergences, with the aim of improving access pathways.
• Gaining a deeper understanding of what real change could look like, directly from those who are experiencing it firsthand.

Excel in shaping the future of market access by turning bold ideas and shared insights into actionable strategies to create more sustainable pathways for patients to access the treatments they need.

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work. Discuss tomorrow’s highlights!